H.C. Wainwright raised the firm’s price target on Syndax to $42 from $38 and keeps a Buy rating on the shares. The company this morning announced positive topline data from the protocol-defined pooled analysis of the pivotal AUGMENT-101 trial cohorts of revumenib in adult and pediatric patients with relapsed or refractor KMT2A-rearranged acute myeloid leukemia and acute lymphoid leukemia, the analyst tells investors in a research note. The firm believes median duration of response could elongate over time. It increased the probability of success for revumenib from 55% to 75%.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on SNDX:
- Syndax announces ‘positive’ results from AUGMENT-101 trial of revumenib
- Syndax put volume heavy and directionally bearish
- Syndax call volume above normal and directionally bullish
- Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
- Kura Oncology initiated with a Buy at BofA